Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study-Reference-Cited by-同舟云学术

Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study

Published:2020-06 Issue:6 Volume:82 Page:1530-1532
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Jo Christine E.,Georgakopoulos Jorge R.,Ladda Matthew,Ighani Arvin,Mufti Asfandyar,Drucker Aaron M.,Piguet Vincent,Yeung Jensen

Funder

Sanofi

Regeneron

AbbVie

Cardiff University

Almirall

Alliance

Beiersdorf UK Ltd

Biotest

Celgene

Dermal

Eli Lilly

Galderma

Genus Pharma

GlobeMicro

Janssen-Cilag

LaRoche-Posay

L'Oréal

LEO Pharma

Meda

Merck Sharp & Dohme

Novartis

Pfizer

Sinclair Pharma

Spirit

Stiefel

Samumed

Thornton Ross

TyPharm

UCB

Publisher

Elsevier BV

Subject

Dermatology

Reference4 articles.

1. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial;Blauvelt;Lancet,2017

2. Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series;Ruiz-Villaverde;Dermatol Ther,2019

3. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator’s Global Assessment: a pooled analysis of data from two phase III trials;Silverberg;Br J Dermatol,2019

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis;JAMA Dermatology;2024-08-07

2. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities;JAAD International;2024-06

3. Assessment of long-term safety and efficacy of Dupilumab therapy in patients with moderate-to-severe atopic dermatitis in the UAE: A real-life observational study;PHARM PRACT-GRANADA;2024

4. Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis;Journal of Clinical Medicine;2024-01-18

5. Considerations for managing elderly patients with atopic dermatitis;Expert Review of Clinical Immunology;2024-01-09